Condition: Post-traumatic Stress Disorder · Post Traumatic Stress Disorder · Stress Disorder · Sponsor: Praxis Precision Medicines
This trial is comprised of a 4-week randomized, double-blind, placebo-controlled treatment period followed by an optional 8-week open-label extension (OLE) period. This trial will evaluate the efficacy and safety of oral PRAX-114 flexibly dosed at 40 to 60 mg for 4 weeks compared to placebo in adults with PTSD. The OLE period consisting of treatment with 40 mg PRAX-114 for 8 weeks will provide additional efficacy and safety data.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Praxis Research Site | Phoenix, Arizona, United States | — |
| Praxis Research Site | Little Rock, Arkansas, United States | — |
| Praxis Research Site | Rogers, Arkansas, United States | — |
| Praxis Research Site | Lemon Grove, California, United States | — |
| Praxis Research Site | Westlake Village, California, United States | — |
| Praxis Research Site | Fort Myers, Florida, United States | — |
| Praxis Research Site | Decatur, Georgia, United States | — |
| Praxis Research Site | Boston, Massachusetts, United States | — |
| Praxis Research Site | Las Vegas, Nevada, United States | — |
| Praxis Research Site | Cincinnati, Ohio, United States | — |
| Praxis Research Site | Dayton, Ohio, United States | — |
| Praxis Research Site | Oklahoma City, Oklahoma, United States | — |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05260541